SLAS2017 - 6th Annual Conference & Exhibition

February 4 - 8, 2017
Washington, D.C., USA

Meet Genedata Screener experts at the SLAS 2017 - 6th Annual Conference & Exhibition in Washington DC, USA.Ask for a demonstration of Genedata Screener 14.0 at at booth #541.

To get more information about Genedata Screener, please contact screener@genedata.com.

 

Genedata Screener for SPR: An Efficient Solution for Small and Large Molecule Screening Analysis Workflows
Spencer Carson, Scientific Account Manager, Genedata Inc., Lexington, MA

Tutorial | Monday, February 6 | 2:00 pm - 2:45 pm | room 143B

Surface plasmon resonance (SPR) is a label-free detection method used to quantify molecular binding affinity and kinetics and to routinely screen libraries of small compounds and fragments as well as large molecules. As SPR screening has become more commonplace and high-throughput with a constant increase in volume and diversity of usage in pharma research, the need has grown for analysis software that can integrate with a variety of instruments and handle large datasets. This live software tutorial will demonstrate the capabilities of Genedata Screener for SPR including efficient data loading, automated processing of sensorgrams, quality control, fitting strategies, and a comparison of small and large molecule screening formats.

 

Effortlessly scale up automated patch clamp research with Genedata Screener
Stephan Steigele, Head of Science, Genedata AG, Basel, Switzerland

Tutorial | Tuesday, February 7 | 9:30 am - 10:15 am | room 143B

This tutorial will show how the capabilities of Genedata Screener for Ion Channel Screening have been expanded with our latest software release. Screener now allows effortless scale-up of automated patch clamp (APC) research with improved experimental overview and comparisons within and across experiments. These new capabilities will be exemplified with our latest Ready-to-Run integration: the Nanion SyncroPatch 384PE. We will show how all QC parameters, compound information and cursor names are directly imported, allowing automatic and coherent evaluation of data, and thereafter present prototypical assays from a compound screening and safety viewpoint, with titrations performed both with cumulative addition and across wells. We will also outline further processing capabilities, e.g. specific control wells enabling per-sweep normalization, before we conclude by providing an enterprise workflow perspective for modern ion channel pharma research.

 

Compound Combination Screening Special Interest Group
Oliver Leven and Rajarshi Guha, Chairs

LinkedIn Group

Wednesday, February 8 | 8:00 am - 9:15 am | room 144B

The mission of the SLAS Compound Combination Screening SIG is to create a knowledge-sharing forum for screening practitioners active in the field of compound combinations. As such, the goal is to mature the field of compound combination screening, aimed at better science that accelerates the pace of drug discovery.

Links:
slas2017.org